Sarepta Therapeutics (NASDAQ:SRPT) Releases Earnings Results, Beats Estimates By $0.12 EPS

Sarepta Therapeutics (NASDAQ:SRPT) posted its quarterly earnings results on Wednesday. The biotechnology company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.38 by $0.12, Zacks reports. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $0.09 during trading on Wednesday, hitting $106.86. 1,074,052 shares of the company’s stock traded hands, compared to its average volume of 823,521. The stock has a market capitalization of $10.21 billion, a price-to-earnings ratio of 85.49 and a beta of 0.75. Sarepta Therapeutics has a 12-month low of $101.15 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50 day moving average of $116.73 and a 200-day moving average of $123.01.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price on the stock. Finally, Evercore ISI decreased their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $176.77.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.